List of Excipients in Branded Drug ATACAND HCT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	CARBOXYMETHYLCELLULOSE CALCIUM
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	FERRIC OXIDE RED
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	FERRIC OXIDE YELLOW
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	HYDROXYPROPYL CELLULOSE
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	LACTOSE MONOHYDRATE
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	MAGNESIUM STEARATE
Physicians Total Care Inc	ATACAND HCT	candesartan cilexetil and hydrochlorothiazide	54868-4729	POLYETHYLENE GLYCOL 8000

ATACAND HCT Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Atacand HCT is a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide. Its commercial opportunity is primarily generic substitution, formulation differentiation, and lifecycle management rather than new-molecule exclusivity. The core product is exposed to generic competition because U.S. regulatory exclusivity and the principal patent barriers have expired. The strongest opportunities are low-cost, bioequivalent tablets; lower-lactose or lactose-free products; improved dissolution formulations; and differentiated fixed-dose strengths that support adherence.

What is Atacand HCT and how is it formulated?

Atacand HCT combines an angiotensin II receptor blocker with a thiazide diuretic.

Product attribute	Atacand HCT profile
Active ingredients	Candesartan cilexetil and hydrochlorothiazide
Drug class	ARB/thiazide antihypertensive
U.S. reference product	Atacand HCT
Reference applicant	AstraZeneca
U.S. dosage form	Immediate-release tablet
Available strengths	16/12.5 mg, 32/12.5 mg and 32/25 mg
FDA pathway for generics	Abbreviated New Drug Application
Biologic risk	None
Biosimilar pathway	Not applicable
Primary commercial issue	Generic price competition and adherence-driven differentiation

Candesartan cilexetil is a prodrug that converts to active candesartan during absorption. It has limited aqueous solubility, making particle size, wetting, granulation, disintegration and dissolution relevant to product performance. Hydrochlorothiazide is more soluble and is unlikely to be the primary formulation constraint.

The approved Atacand HCT labeling identifies a conventional tablet excipient system that includes lactose monohydrate, corn starch, hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate. Tablet-color formulations may also contain iron oxide pigments, depending on strength and product presentation.[1]

What excipients are used in Atacand HCT?

The reference formulation uses a conventional oral-tablet platform.

Excipient	Functional role	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Low cost, established safety profile; creates an opportunity for lactose-free alternatives
Corn starch	Filler and disintegration support	Supports robust tablet breakup and low-cost manufacture
Hydroxypropyl cellulose	Binder	Controls granule strength and tablet integrity
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet disintegration
Magnesium stearate	Lubricant	Improves manufacturing throughput but can retard wetting or dissolution if overused
Iron oxides, where applicable	Colorant	Supports strength identification and product differentiation

The excipient strategy is uncomplicated, which reduces manufacturing risk. The key development challenge is maintaining candesartan cilexetil dissolution and bioequivalence while modifying the inactive ingredients.

A generic applicant does not need to duplicate every excipient in the reference product. FDA permits differences in inactive ingredients when the formulation remains safe and the product meets applicable pharmaceutical equivalence and bioequivalence standards.[2] The practical constraint is that an excipient change can alter tablet porosity, wetting, disintegration, dissolution, stability or gastrointestinal exposure.

How should a company design a generic Atacand HCT excipient system?

A conventional generic strategy should prioritize manufacturing robustness over novelty.

Base formulation strategy

A cost-efficient formulation would use:

• Lactose or microcrystalline cellulose as the principal diluent
• Crospovidone or croscarmellose sodium as the disintegrant
• Hypromellose or hydroxypropyl cellulose as the binder
• Magnesium stearate or sodium stearyl fumarate as the lubricant
• A limited amount of colloidal silicon dioxide if flow improvement is needed

The formulation should control the following variables:

1. Candesartan cilexetil particle-size distribution
2. Drug loading uniformity across the three strengths
3. Granule density and porosity
4. Lubrication time and lubricant concentration
5. Tablet hardness and friability
6. Dissolution across multiple pH conditions
7. Moisture exposure during granulation and storage

The product should be developed as a strength-proportional platform where practical. This can reduce tooling, analytical validation and stability costs. A company may use common granulation technology across 16/12.5 mg, 32/12.5 mg and 32/25 mg tablets, but the highest-strength product may require separate optimization because candesartan cilexetil loading and tablet mass affect blend uniformity.

Lactose-free strategy

A lactose-free formulation is the clearest excipient-based differentiation opportunity. Lactose can be replaced by microcrystalline cellulose, mannitol, dibasic calcium phosphate or a co-processed filler.

Substitute	Advantages	Risks
Microcrystalline cellulose	Strong compaction and broad supplier base	Can increase tablet weight and alter disintegration
Mannitol	Good mouthfeel and low hygroscopicity	Higher cost; may require lubricant optimization
Dibasic calcium phosphate	Low moisture sensitivity and good flow	May affect dissolution and tablet hardness
Isomalt or co-processed excipient	Useful for direct compression	Higher cost and limited economic benefit for a low-price generic

The commercial case for lactose removal is strongest in markets and payer channels where allergen, intolerance or excipient-label preferences influence prescribing or dispensing. It is weaker as a pure price strategy because the alternative excipients generally cost more than lactose.

Low-moisture formulation strategy

Candesartan cilexetil may be sensitive to formulation and storage conditions because ester hydrolysis and solid-state changes can affect performance. A low-moisture platform using direct compression, dry granulation, moisture-barrier packaging and controlled water activity can reduce stability risk.

Blister packaging may provide stronger moisture protection than standard high-density polyethylene bottles, but packaging cost can materially reduce generic margins. The economic case depends on whether the formulation requires the protection or whether a bottle with a desiccant is sufficient.

What formulation patents could protect an Atacand HCT follow-on product?

The commercial value of formulation patenting depends on whether the product creates a clinically or regulatory meaningful distinction.

Potential claim areas include:

• Reduced-particle-size candesartan cilexetil
• Amorphous or co-amorphous drug forms
• Solid dispersions or inclusion complexes
• Surfactant-assisted dissolution systems
• Specific granulation and milling processes
• Moisture-controlled tablets
• Lactose-free compositions
• Modified disintegration or dissolution profiles
• Fixed-dose products with new dose ratios
• Sprinkle, orally disintegrating or liquid formulations
• Taste-masked pediatric products

A simple substitution of lactose with microcrystalline cellulose is unlikely to create strong, durable protection by itself. Patent value improves when the excipient system solves a measurable technical problem, such as a defined dissolution defect, stability limitation or bioavailability issue.

A formulation patent should include composition claims, process claims and measurable performance limitations. Useful limitations may include dissolution windows, impurity thresholds, particle-size ranges, water activity, tablet tensile strength or stability after defined storage conditions. Claims based only on a list of routine excipients face a higher obviousness risk.

What patents protect Atacand HCT, and when did exclusivity end?

Atacand HCT is no longer protected by commercially meaningful U.S. exclusivity.

The underlying candesartan technology was associated with historical patent protection, including U.S. Patent No. 5,703,110. Later patents covered combination, formulation or related product subject matter. The original patent estate has expired, and Atacand HCT does not have current new chemical entity exclusivity.[3]

Exclusivity category	Atacand HCT status
New chemical entity exclusivity	Expired
Original candesartan compound protection	Expired
Combination-product protection	Expired or no longer blocking routine ANDA entry
Pediatric exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Current Orange Book blocking position	No active commercial barrier identified for ordinary generic entry

The relevant business conclusion is that a new entrant should not rely on the legacy Atacand HCT patent estate for protection. Any current exclusivity would need to come from a new formulation, dosage form, manufacturing process or method of use.

What is the Orange Book status of Atacand HCT?

The FDA Orange Book identifies Atacand HCT as the reference product for candesartan cilexetil and hydrochlorothiazide tablets. The product is not protected by a current regulatory exclusivity period that would prevent ANDA approval.[3]

A generic applicant would normally address any listed patents through one of the ANDA patent-certification pathways. For a product with expired listed patents, the practical route is usually a Paragraph III certification or a certification reflecting that no unexpired patent blocks approval. A Paragraph IV challenge is principally relevant when an unexpired patent remains listed.

Which companies are challenging Atacand HCT?

The competitive field consists mainly of generic manufacturers rather than branded patent challengers. U.S. generic suppliers have marketed candesartan cilexetil and hydrochlorothiazide tablets in the same dosage strengths or comparable strengths, subject to FDA approval and product availability.

Typical competitors include manufacturers with established cardiovascular portfolios, including Indian, Israeli and U.S.-based generic companies. Competitive intensity is determined by:

• Number of approved ANDAs
• Current wholesaler supply
• Contracting with pharmacy benefit managers
• National versus regional distribution
• Ability to supply all three strengths
• Manufacturing cost and API sourcing
• FDA inspection and warning-letter history
• Product discontinuation rates

Atacand HCT is a weak candidate for a high-cost Paragraph IV strategy because the principal commercial patents have expired. A new entrant would compete through supply reliability, low cost, packaging, private-label partnerships and dosage-form differentiation.

What generic entry risks exist for Atacand HCT?

The principal generic risks are regulatory and operational rather than patent-based.

Bioequivalence risk

Candesartan cilexetil dissolution can be sensitive to particle size, wetting and excipient selection. A formulation that matches the reference tablet in assay but releases candesartan cilexetil differently may fail dissolution or produce an unacceptable pharmacokinetic profile.

The development program should include comparative dissolution using multiple media and discriminating conditions. Formulation changes should be evaluated against both active ingredients, even though candesartan cilexetil is likely to be the more sensitive component.

Manufacturing risk

The combination product requires uniform distribution of two active ingredients with different dose levels and physical properties. The 32/12.5 mg product has a relatively high candesartan-to-hydrochlorothiazide ratio, while the 32/25 mg product doubles the hydrochlorothiazide load. A common blend process may not perform equally across all strengths.

Supply-chain risk

Candesartan cilexetil is a specialized API with fewer suppliers than common tablet excipients. API qualification, impurity control and backup sourcing can be more important than excipient cost. A company that qualifies only one API source may face avoidable interruption risk.

How strong is the patent estate for a new Atacand HCT formulation?

A new formulation estate can be moderately strong if it satisfies three conditions:

1. It delivers a demonstrated technical advantage.
2. The advantage is difficult to obtain through routine formulation work.
3. The claims cover commercially relevant products and manufacturing routes.

The strongest candidates are improved dissolution systems for low-solubility candesartan cilexetil, stable low-moisture compositions and new dosage forms with a defined patient or adherence benefit.

The weakest candidates are broad claims covering standard fillers, binders, disintegrants and lubricants without a specific performance result. Such claims may be vulnerable to obviousness challenges and may not justify a premium product price.

International protection should be assessed separately. Patent term, examination outcomes, Orange Book listing rules and generic litigation procedures differ between the United States, Europe, Japan, China, India and other markets. A U.S. formulation patent does not automatically create equivalent protection in Europe or emerging markets.

What commercial opportunities exist beyond a standard generic?

1. Authorized-generic or private-label supply

A manufacturer can pursue supply agreements with distributors, pharmacy chains or integrated health systems. The product is well suited to private-label commercialization because the active ingredients, dosage strengths and prescribing category are established.

2. Lactose-free tablets

A lactose-free product can target patients and prescribers who prefer to avoid lactose. The differentiation is commercially credible but likely modest. It should be paired with clear labeling and supply reliability rather than positioned as a premium therapeutic innovation.

3. Adherence-oriented fixed-dose combinations

The product already reduces pill burden by combining an ARB and diuretic. Additional opportunity lies in broader hypertension combinations, such as candesartan with a calcium-channel blocker, subject to clinical, regulatory and patent analysis.

4. Orally disintegrating or sprinkle formulations

These products could target patients with swallowing difficulty, older adults and selected adherence populations. They would likely require a 505(b)(2) application or another regulatory pathway if the dosage form creates a meaningful difference from the approved tablet. Taste masking, dose uniformity and moisture protection would become central development issues.[4]

5. Pediatric or geriatric presentations

A lower-dose, dispersible or liquid presentation could address administration challenges. Hydrochlorothiazide dosing, taste and stability would need careful control. Pediatric commercialization would require clinical and regulatory support that exceeds the requirements of a routine ANDA.

6. Emerging-market manufacturing

Local production or regional licensing may create value in markets where branded products remain expensive or generic penetration is uneven. The principal barriers are API registration, local bioequivalence requirements, manufacturing authorization and price controls.

How does Atacand HCT compare with other ARB/thiazide combinations?

Combination	Commercial position	Formulation opportunity
Candesartan/HCTZ	Established ARB/thiazide with generic availability	Dissolution optimization and lactose-free positioning
Losartan/HCTZ	Broad generic competition and lower cost	Limited price-based differentiation
Valsartan/HCTZ	Established combination with substantial generic exposure	Manufacturing scale and supply reliability
Irbesartan/HCTZ	Generic combination with adherence value	Alternative strengths and regional licensing
Olmesartan/HCTZ	Generic competition and strong branded history	Formulation differentiation is difficult

Candesartan/HCTZ may support a higher value proposition in selected prescriber segments because candesartan has a strong hypertension and heart-failure evidence base. That clinical positioning does not, by itself, protect the formulation from generic substitution.

What is the litigation and settlement outlook?

Current Atacand HCT litigation risk is low relative to products with active listed patents. A new conventional generic is unlikely to require a major patent settlement because the legacy exclusivity period has ended. Litigation risk becomes more relevant if a company develops:

• A novel extended-release product
• A proprietary solid dispersion
• A new fixed-dose ratio
• A pediatric or orally disintegrating formulation
• A manufacturing process that overlaps an active third-party patent

A formulation developer should conduct freedom-to-operate analysis across candesartan cilexetil solid forms, particle engineering, excipient systems, tablet manufacturing and alternative dosage forms. The relevant risk may come from third-party formulation patents rather than AstraZeneca’s historical Atacand HCT patents.

Key Takeaways

• Atacand HCT is an immediate-release fixed-dose tablet containing candesartan cilexetil and hydrochlorothiazide.
• Its reference excipient system is conventional: lactose, corn starch, hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate, with colorants in applicable strengths.
• The U.S. product has no current regulatory exclusivity or commercially meaningful blocking patent position.
• The strongest generic formulation risk is dissolution and bioequivalence performance for candesartan cilexetil.
• Lactose-free, low-moisture and adherence-oriented formulations offer the most credible differentiation.
• A standard generic is primarily a scale, sourcing and contracting business.
• A novel dosage form or technically improved formulation could support a 505(b)(2) strategy and new patent protection.
• Biosimilar analysis is irrelevant because Atacand HCT contains small-molecule active ingredients.
• Litigation risk is low for ordinary generic entry and higher for novel formulation or delivery-system products.

FAQs

Can a generic Atacand HCT tablet use different excipients?

Yes. An ANDA may use inactive ingredients that differ from the reference product if the formulation satisfies FDA safety, quality, pharmaceutical-equivalence and bioequivalence requirements.

Is lactose-free Atacand HCT commercially attractive?

It is a viable niche strategy, especially for institutional buyers and patients seeking lactose-free medicines. The opportunity is stronger when supported by reliable supply and broad strength availability.

Does candesartan cilexetil require a solubility-enhancing excipient?

Not necessarily. A conventional formulation can be bioequivalent, but particle engineering, wetting agents, surfactants or solid-dispersion technology may improve dissolution and expand formulation options.

Would an orally disintegrating Atacand HCT product qualify for an ANDA?

The regulatory pathway depends on whether the new dosage form is sufficiently equivalent to the reference product. A materially different dosage form may require a 505(b)(2) application rather than a standard ANDA.

What is the most defensible patent strategy for a new Atacand HCT product?

The strongest strategy is a layered estate covering a demonstrated dissolution or stability improvement, the composition that produces it, the manufacturing process and clinically relevant alternative dosage forms.

References

1. AstraZeneca Pharmaceuticals LP. (2022). Atacand HCT prescribing information. U.S. Food and Drug Administration, DailyMed.
2. U.S. Food and Drug Administration. (2019). Inactive ingredient database. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
4. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). https://www.fda.gov
5. U.S. Patent No. 5,703,110. (1997). Benzimidazole derivatives. United States Patent and Trademark Office.